MA39294B1 - Polythérapie contre le cancer - Google Patents

Polythérapie contre le cancer

Info

Publication number
MA39294B1
MA39294B1 MA39294A MA39294A MA39294B1 MA 39294 B1 MA39294 B1 MA 39294B1 MA 39294 A MA39294 A MA 39294A MA 39294 A MA39294 A MA 39294A MA 39294 B1 MA39294 B1 MA 39294B1
Authority
MA
Morocco
Prior art keywords
combytherapy
against cancer
fluoro
benzoimidazol
piperazin
Prior art date
Application number
MA39294A
Other languages
English (en)
Other versions
MA39294A1 (fr
Inventor
Edward Chan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39294A1 publication Critical patent/MA39294A1/fr
Publication of MA39294B1 publication Critical patent/MA39294B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne la préparation de médicaments destinés à être utilisés dans le traitement et des méthodes de traitement du cancer du poumon non à petites cellules chez un patient comprenant: de la [5-(4-éthyl-pipérazin-1-ylméthyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-méthyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine ou un sel pharmaceutiquement acceptable de celle-ci, en combinaison, tel qu'également décrit dans l'invention, avec un anticorps anti-vegfr2, de préférence, le ramucirumab.
MA39294A 2014-02-26 2015-02-19 Polythérapie contre le cancer MA39294B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944811P 2014-02-26 2014-02-26
PCT/US2015/016529 WO2015130540A1 (fr) 2014-02-26 2015-02-19 Polythérapie contre le cancer

Publications (2)

Publication Number Publication Date
MA39294A1 MA39294A1 (fr) 2018-06-29
MA39294B1 true MA39294B1 (fr) 2018-12-31

Family

ID=52630493

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39294A MA39294B1 (fr) 2014-02-26 2015-02-19 Polythérapie contre le cancer

Country Status (18)

Country Link
US (1) US10238656B2 (fr)
EP (1) EP3110444B1 (fr)
JP (1) JP5948525B1 (fr)
KR (1) KR20160111001A (fr)
CN (1) CN106029097A (fr)
AP (1) AP2016009402A0 (fr)
AU (1) AU2015223359B2 (fr)
BR (1) BR112016016880A2 (fr)
CA (1) CA2936558A1 (fr)
EA (1) EA201691385A1 (fr)
ES (1) ES2659424T3 (fr)
IL (1) IL246761A0 (fr)
MA (1) MA39294B1 (fr)
MX (1) MX2016011045A (fr)
MY (1) MY176219A (fr)
SG (1) SG11201606958YA (fr)
TW (1) TWI558399B (fr)
WO (1) WO2015130540A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201625304A (zh) * 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
CN108883182A (zh) * 2016-04-15 2018-11-23 伊莱利利公司 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
WO2018045993A1 (fr) * 2016-09-09 2018-03-15 正大天晴药业集团股份有限公司 Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
CA3095922A1 (fr) 2018-04-05 2019-10-10 Johnson Matthey Public Limited Company Formes solides d'abemaciclib, leur utilisation et leur preparation
US20210163605A1 (en) * 2018-04-06 2021-06-03 Eli Lilly And Company Ramucirumab for the treatment of cancers in pediatric patients
TW202110454A (zh) * 2019-05-30 2021-03-16 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2021030843A1 (fr) * 2019-08-13 2021-02-18 Johnson Matthey Public Limited Company Formes solides d'abemaciclib, leur utilisation et leur préparation
WO2024141995A1 (fr) * 2022-12-28 2024-07-04 Novocure Gmbh Compositions, systèmes et méthodes de traitement du cancer à l'aide de champs de traitement de tumeur et d'anticorps anti-vegfr-2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6

Also Published As

Publication number Publication date
WO2015130540A1 (fr) 2015-09-03
EA201691385A1 (ru) 2016-12-30
JP5948525B1 (ja) 2016-07-06
TW201542209A (zh) 2015-11-16
AU2015223359A1 (en) 2016-08-11
BR112016016880A2 (pt) 2017-10-03
US10238656B2 (en) 2019-03-26
MY176219A (en) 2020-07-24
EP3110444B1 (fr) 2018-01-03
CA2936558A1 (fr) 2015-09-03
TWI558399B (zh) 2016-11-21
ES2659424T3 (es) 2018-03-15
SG11201606958YA (en) 2016-09-29
JP2016521262A (ja) 2016-07-21
AP2016009402A0 (en) 2016-08-31
AU2015223359B2 (en) 2017-06-01
EP3110444A1 (fr) 2017-01-04
CN106029097A (zh) 2016-10-12
MA39294A1 (fr) 2018-06-29
US20170173013A1 (en) 2017-06-22
IL246761A0 (en) 2016-08-31
KR20160111001A (ko) 2016-09-23
MX2016011045A (es) 2016-10-28

Similar Documents

Publication Publication Date Title
MA39294A1 (fr) Polythérapie contre le cancer
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
SG10201803331PA (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MY179392A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MX2019001900A (es) Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma.
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
EP4249076A3 (fr) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide en tant qu'inhibiteur btk
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
WO2013169864A3 (fr) Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
EA201690998A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
GEP20257716B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MX2019012758A (es) Regimen terapeutico de 2-amino-1-(2-(4-fluorofenil)-3-(4-fluorofen ilamino)-8,8-dimetil-5,6-dihidroimidazo [1,2-a]pirazin-7(8h)-il)et anona y combinaciones de la misma.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
PH12015500060A1 (en) Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl) compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benz
Patel Periostitis: case report